15 August 2017

Holiday Inn, Manchester City Centre, 25 Aytoun St, Manchester M1 3AE

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Appraisal of sarilumab for previously treated moderate to severe active rheumatoid arthritis [ID994]
           4.1. Declarations of interest – Part 1 only (open session)
           4.2. Introduction by the Chair, Professor Andrew Stevens – Part 1 only (open session)
           4.3. Presentation by the lead team, Professor Andrew Renehan, Dr Nigel Langford and Mr David Chandler  Part 1 AND Part 2 (open and closed session)
           4.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  5. Appraisal of aflibercept for treating myopic choroidal neovascularisation [ID952]
            5.1. Declarations of interest – Part 1 only (open session)
            5.2. Introduction by the  Chair, Professor Andrew Stevens – Part 1 only (open session)
            5.3. Presentation by the NICE technical team – Part 1 AND Part 2 (open and closed session)
            5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of nivolumab for treatring metastatic, squamous, non-small-cell lung cancer after chemotherapy [ID811]
    The nature of this technology appraisal discussion is commercially sensitive and will take place in Part 2 only (Part 2 sessions are closed to public observers)
            6.1. Declarations of interest  Part 2 only (closed session)
            6.2. Introduction by the  Chair, Professor Andrew Stevens  Part 2 only (closed session)
            6.3. Presentation by the NICE technical team  Part 2 only (closed session)
            6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD)  Part 2 only (closed session)
  7. Appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer [ID900]
    The nature of this technology appraisal discussion is commercially sensitive and will take place in Part 2 only (Part 2 sessions are closed to public observers)
            7.1. Declarations of interest  Part 2 only (closed session)
            7.2. Introduction by the  Chair, Professor Andrew Stevens  Part 2 only (closed session)
            7.3. Presentation by the NICE technical team  Part 2 only (closed session)
            7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD)  Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Wednesday 13 September 2017 at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Tuesday 1 August  2017Please note that it may not be possible to accept late requests. 
  • Should you have any queries regarding attending this meeting, please contact the Meetings in Public Coordinator Sandra Robinson.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 18 July 2017 to 01 August 2017
Registration is closed.